The growing analytical toolbox for complex drugs: Assessment of NBCD bioequivalence
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Presentation
- By: MCNEIL, Scott (Nanotechnology Characterization Lab (NCL), Frederick National Laboratory for Cancer Research, Frederick, United States)
- Co-author(s): Scott Mcneil: Nanotechnology Characterization Laboratory Cancer Research Technology Program -Leidos Biomedical Research, Inc , Frederick National Lab, Frederick, United States
Nanomedicines, a subclass of NBCDs, often demonstrate unique therapeutic advantages over the legacy formulated drug. By altering the drug’s pharmacokinetic properties, nanomedicines can increase half-life, enhance distribution to target tissues, and decrease off-target toxicity of the API. By definition, nanoscale NBCDs are complex and cannot be.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.